Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
We are looking for promising preclinical candidates in Oncology. Our offer is to share the risk on selected projects from the preclinical candidate stage to phase IIa.
A win-win alliance
Mobilizing our extensive experience in the selection of effective drug candidates in oncology, Oncodesign will select anti-cancer compounds meeting our efficacy criteria by carrying out a preclinical PoC completely at our own expense as part of an acceleration program. If this stage is successful, the compound will be able to continue its development until phase IIa, funded by Oncofast track, in exchange for an exclusive license for the development company. This will be negotiated with partner pharmaceutical companies.
Oncodesign offers the research project holder the opportunity to transform its high-potential active compound into a promising therapeutic solution in oncology or immuno-oncology through a win-win risk sharing alliance.
Working with the project owner, we bridge the gap between product discovery and the real-world patient by setting up a drug development program that combines a pharmaceutical approach to define the most appropriate target product profile and the agility of Oncodesign in order to design and deliver an accelerated drug development program, from discovery up to the phase II proof-of-concept study.